Jason Westin, MD, MS, FACP, MD Anderson Cancer Center
Articles by Jason Westin, MD, MS, FACP, MD Anderson Cancer Center
Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.
Management of Diffuse Large B-Cell Lymphoma: Data From ASCO 2023
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.
Bridging Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center Before closing out their discussion on the relapsed/refractory setting of diffuse large B-cell lymphoma, panelists identify best practices in bridging therapy.
Sequencing Novel Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.
What is the Role of Bispecifics in Relapsed/Refractory DLBCL?
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.
Relapsed/Refractory DLBCL: Managing Patients on CAR T-Cell Therapy
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.
Factors That Inform Sequencing of Therapy in Relapsed/Refractory DLBCL
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Lisocabtagene Maraleucel
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Axicabtagene Ciloleucel
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.
Tafasitamab + Lenalidomide Therapy in Relapsed/Refractory DLBCL
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
Factors in Selecting Treatment for Relapsed/Refractory DLBCL
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Overview of Relapsed/Refractory DLBCL and Management Strategies
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Joanna M. Rhodes, MD, MSCE,Yucai Wang, MD, PhD, Mayo Clinic,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Hayder M. Saeed, MD, Moffitt Cancer Center Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.
Diagnosis and Frontline Management of Diffuse Large B-Cell Lymphoma
ByJoanna M. Rhodes, MD, MSCE,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Yucai Wang, MD, PhD, Mayo Clinic,Hayder M. Saeed, MD, Moffitt Cancer Center Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.
How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients
ByDavid L. Porter, MD, University of Pennsylvania,Jason Westin, MD, MS, FACP, MD Anderson Cancer Center,Elizabeth Budde, MD, PhD 
Jason Westin, MD, MS, FACP, discusses challenges with treating patients with large cell lymphoma.
Jason Westin, MD, MS, FACP, discusses the role of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.
Jason Westin, MD, MS, FACP, discusses the potential for a chemotherapy-free future in large cell lymphoma.
Diagnosis and Frontline Management of Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care
Overview of Relapsed/Refractory DLBCL and Management Strategies
Tafasitamab + Lenalidomide Therapy in Relapsed/Refractory DLBCL